Publications récentes de ResaFLU

Novel antiviral compounds and combination therapy for influenza viruses.

Boivin G, Rosa-Calatrava M, Lina B.

Virologie (Montrouge). 2019 Dec 1;23(6):325-328.

doi: 10.1684/vir.2019.0802

Advances in Influenza Virus-Like Particles bioprocesses.

Durous L, Rosa-Calatrava M and Petiot E.

Expert Rev Vaccines. 2019 Dec 12.

doi: 10.1080/14760584.2019.1704262.

Risk Mapping of Influenza D Virus Occurrence in Ruminants and Swine in Togo Using a Spatial Multicriteria Decision Analysis Approach.

Fusade-Boyer M, Pato PS, Komlan M, Dogno K, Batawui K, Go-Maro E, McKenzie P,

Guinat C, Secula A, Paul M, Webby RJ, Tran A, Waret-Szkuta A, Ducatez MF.

Viruses. 2020 Jan 21;12(2).

pii: E128. doi: 10.3390/v12020128.

Entraide

Nous sommes toujours à la recherche d'un bon anticorps commercial anti-NS2(NEP). Avez-vous une référence à nous conseiller ?

Merci ! Nadia et l'équipe IP-VIC

Best-of des articles de synthèse

Image : Hans Braxmeier, Pixabay

Wash Your Hands

Ruper Beale

London Review of Books

Vol. 42 No. 5 · 5 March 2020

Compounds with therapeutic potential against novel respiratory 2019 coronavirus.

Martinez MA.

Antimicrob Agents Chemother. 2020 Mar 9.

doi: 10.1128/AAC.00399-20.

Microtubules in Influenza Virus Entry and Egress.

Simpson C, Yamauchi Y.

Viruses. 2020 Jan 17;12(1). pii: E117.

doi: 10.3390/v12010117.

Critical care management of adults with community-acquired severe respiratory viral infection.

Arabi YM, Fowler R, Hayden FG.

Intensive Care Med. 2020 Feb;46(2):315-328.

doi: 10.1007/s00134-020-05943-5.

Next-generation influenza vaccines: opportunities and challenges.

Wei CJ, Crank MC, Shiver J, Graham BS, Mascola JR, Nabel GJ.

Nat Rev Drug Discov. 2020 Feb 14.

doi: 10.1038/s41573-019-0056-x